Revolution Medicines, Inc. Increase Decrease In Operating Lease Liability
Revolution Medicines, Inc. (RVMD) reported Increase Decrease In Operating Lease Liability of -$4.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- Revolution Medicines, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$2.13M.
- Revolution Medicines, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$2.07M.
- Revolution Medicines, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $241.00K, a 75.73% decline year-over-year.
- Revolution Medicines, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $1.86M.
- Revolution Medicines, Inc. increase decrease in operating lease liability for fiscal 2025 was -$957.00K.
- Revolution Medicines, Inc. increase decrease in operating lease liability for fiscal 2024 was -$245.00K.
- Revolution Medicines, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.53M.
- Revolution Medicines, Inc. increase decrease in operating lease liability for fiscal 2022 was -$2.43M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.21M 10-Q · filed 2026-08-05 | -$3.97M derived: sum of 3 quarters · filed 2026-08-05 | -$2.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$2.07M 10-Q · filed 2026-05-06 | -$1.83M derived: sum of 2 quarters · filed 2026-05-06 | $26.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.10M derived: sum of 2 quarters · filed 2026-02-25 | $544.00K derived: sum of 3 quarters · filed 2026-08-05 | -$957.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $303.00K derived: sum of 2 quarters · filed 2026-08-05 | -$1.20M 10-Q · filed 2025-11-05 | -$205.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.06M 10-Q · filed 2026-08-05 | -$2.06M derived: sum of 3 quarters · filed 2026-08-05 | -$2.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.50M 10-Q · filed 2026-05-06 | -$508.00K derived: sum of 2 quarters · filed 2026-05-06 | -$1.21M derived: sum of 3 quarters · filed 2026-05-06 | -$1.83M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $993.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $288.00K derived: sum of 2 quarters · filed 2026-02-25 | -$330.00K derived: sum of 3 quarters · filed 2026-02-25 | -$245.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | -$705.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.32M derived: sum of 2 quarters · filed 2025-11-05 | -$1.24M 10-Q · filed 2025-11-05 | -$1.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$618.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$533.00K 10-Q · filed 2025-08-06 | -$708.00K derived: sum of 3 quarters · filed 2026-02-25 | -$1.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $85.00K 10-Q · filed 2025-05-07 | -$90.00K derived: sum of 2 quarters · filed 2026-02-25 | -$498.00K derived: sum of 3 quarters · filed 2026-02-25 | -$553.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$583.00K derived: sum of 2 quarters · filed 2026-02-25 | -$638.00K derived: sum of 3 quarters · filed 2026-02-25 | -$1.53M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$408.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$463.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.36M 10-Q · filed 2024-11-06 | -$2.35M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$949.00K 10-Q · filed 2024-08-07 | -$1.94M derived: sum of 3 quarters · filed 2025-02-26 | -$1.70M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$894.00K 10-Q · filed 2024-05-08 | -$1.89M derived: sum of 2 quarters · filed 2025-02-26 | -$1.64M derived: sum of 3 quarters · filed 2025-02-26 | -$2.60M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$995.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$747.00K derived: sum of 2 quarters · filed 2025-02-26 | -$1.71M derived: sum of 3 quarters · filed 2025-02-26 | -$2.43M 10-K · filed 2025-02-26 |
| 2022-09-30 | $248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$714.00K derived: sum of 2 quarters · filed 2023-11-06 | -$1.43M 10-Q · filed 2023-11-06 | -$2.02M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$962.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.68M 10-Q · filed 2023-08-08 | -$2.27M derived: sum of 3 quarters · filed 2024-02-26 | -$2.98M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$719.00K 10-Q · filed 2023-05-08 | -$1.31M derived: sum of 2 quarters · filed 2024-02-26 | -$2.02M derived: sum of 3 quarters · filed 2024-02-26 | -$1.52M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$1.30M derived: sum of 2 quarters · filed 2024-02-26 | -$798.00K derived: sum of 3 quarters · filed 2024-02-26 | -$1.47M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$208.00K derived: sum of 2 quarters · filed 2022-11-07 | -$878.00K 10-Q · filed 2022-11-07 | -$1.53M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$172.00K 10-Q · filed 2022-08-09 | -$822.00K derived: sum of 3 quarters · filed 2023-02-27 | |
| 2021-03-31 | -$670.00K 10-Q · filed 2022-05-09 | -$1.32M derived: sum of 2 quarters · filed 2023-02-27 | ||
| 2020-12-31 | -$650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$2.56M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | -$1.92M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |